Noticias de GNPX_US

30/04/2026 GNPX_US — Yahoo Finance

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

30/04/2026 GNPX_US — Morningstar ES ← EN

Genprex recibe una concesión de patente de la Oficina de Patentes de Israel para la combinación de la terapia génica Reqorsa® y anticuerpos PD-1 para tratar el cáncer

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

30/04/2026 GNPX_US — Stock Titan

Israel grants Genprex (NASDAQ: GNPX) patent for REQORSA lung cancer use

30/04/2026 GNPX_US — TipRanks

Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel

29/04/2026 GNPX_US — Stock Titan

Genprex (NASDAQ: GNPX) seeks approval for equity plan and reverse stock split

29/04/2026 GNPX_US — Investing.com Australia ES ← EN

Colaboradores de Genprex presentarán datos sobre terapia génica para la diabetes en la reunión de mayo Por Investing.com

Genprex collaborators to present diabetes gene therapy data at May meeting By Investing.com

28/04/2026 GNPX_US — BioSpace ES ← EN

Colaboradores de Genprex presentarán datos preclínicos positivos sobre la terapia génica para la diabetes tipo 2 en la reunión anual de 2026 de la Sociedad Estadounidense de Terapia Génica y Celular

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — Investing.com UK

Genprex collaborators to present diabetes gene therapy data at May meeting

28/04/2026 GNPX_US — Investing.com South Africa

Genprex collaborators to present diabetes gene therapy data at May meeting By Investing.com

28/04/2026 GNPX_US — Investing.com ES ← EN

Colaboradores de Genprex presentarán datos sobre terapia génica para la diabetes en la reunión de mayo

Genprex collaborators to present diabetes gene therapy data at May meeting

28/04/2026 GNPX_US — MarketScreener ES ← EN

Colaboradores de Genprex presentarán datos preclínicos positivos sobre la terapia génica para la diabetes tipo 2 en la reunión anual de 2026 de la Sociedad Estadounidense de Terapia Génica y Celular

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — ChartMill

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — Morningstar

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — Barchart

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — Fidelity

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

28/04/2026 GNPX_US — Stock Titan

Genprex (GNPX) shows GPX-002 gene therapy reversed hyperglycemia in T2D mice

28/04/2026 GNPX_US — TipRanks

Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy